Toyama et al used a score based on hematologic and cytogenetic findings to predict the prognosis for patients with the myelodysplasia syndrome. This can help identify those patients who may require more aggressive management and monitoring. The authors are from the Tokyo Medical College and the Japanese Study Group for Intractable Hematopoietic Disease.
Parameters:
(1) hematologic score, based on the Bournemouth score (see above)
(1a) neutrophil count
(1b) hemoglobin
(1c) platelet count
(1d) percent blasts in the bone marrow
(2) cytogenetic score
|
Parameter |
Finding |
Points |
|
neutrophil count |
< 2,500 per µL |
1 |
|
|
>= 2,500 per µL |
0 |
|
hemoglobin level |
< 10 g/dL |
1 |
|
|
>= 10 g/dL |
0 |
|
platelet count |
< 100,000 per µL |
1 |
|
|
>= 100,000 per µL |
0 |
|
blasts in bone marrow |
>= 5% |
1 |
|
|
< 5% |
0 |
|
cytogenetic abnormality |
3 or more aberrations (complex) |
3 |
|
|
2 aberrations |
1 |
|
|
+8 (trisomy 8) |
1 |
|
|
-7/7q- (partial loss of the long arm of chromosome 7) |
1 |
|
|
all other abnormalities |
0 |
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 7
• The higher the score the worse the prognosis.
|
Total Score |
Group |
5 Year Survival |
Median Survival |
|
0, 1 or 2 |
low |
60% |
> 10 years |
|
3 or 4 |
moderate |
43% |
3 years |
|
5, 6 or 7 |
high |
7% |
7 months |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
